If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Research Agreement with Arysta LifeScience

27 Apr 2012 11:49

RNS Number : 2414C
Plant Health Care PLC
27 April 2012
 

27 April 2012

 

Plant Health Care plc

 

PLANT HEALTH CARE TO CONDUCT RESEARCH ON

HARPIN PROTEIN WITH ARYSTA LIFESCIENCE

 

 

Plant Health Care, a leading provider of naturally-derived products to the global agriculture markets, announces that it has signed a research agreement with Arysta LifeScience to evaluate Harpin commercially as a foliar spray in combination with a number of Arysta LifeScience's products.

 

 

Harpin is a leading PHC product and has been shown to increase yields significantly on a variety of crops when applied alone or in combination with other active ingredients. Arysta LifeScience will test Harpin formulations in combination with a number of its actives. Harpin technology offers yield improvement as a result of suppression of pests, such as nematodes, and defense against damaging diseases, as well as additive plant health benefits. Under this agreement, improvements in yield, plant health and product efficacy will be evaluated in a range of crops and environmental situations.

 

 

John Brady, CEO of Plant Health Care, commented: "We are excited to establish a testing programme with Arysta LifeScience, an innovative global player in the crop protection industry with annual sales of $1.6 billion. Arysta LifeScience has been highly successful in incorporating new technologies into its extensive product portfolio and, with its global reach, a successful outcome will be a major benefit to PHC. We are optimistic that Arysta LifeScience's testing efforts will lead to eventual commercial development of an innovative high return product for growers worldwide."

 

 

Bill Lewis, head of global business initiatives, Arysta LifeScience, said: "Harpin technology has the potential to bring additional value to Arysta LifeScience's existing line of products and we are excited about the opportunity to evaluate the Harpin technology."

 

 

- ENDS -

 

 

About Plant Health Care plc: Plant Health Care plc ("PHC") is a leading provider of naturally-derived products for plants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the United States, PHC currently has approximately 40 employees and has operations in the United States, Mexico, the United Kingdom, Spain and the Netherlands. The Company's ordinary shares have been quoted on the Alternative Investment Market ("AIM") of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") since February 2010 (ticker symbol/ mnemonic: PHC).

 

PHC's products are aimed at agriculture industries and are environmentally beneficial. Through the commercialisation of these products, PHC is capitalising on current long-term trends toward natural systems and biological products for plant care and soil and water management. Further information is available at: www.planthealthcare.com.

 

 

 

For further information, please contact:

 

 

 

Plant Health Care plc

John Brady, Chief Executive Officer

Tel: +1-603-525-3702

jabrady@planthealthcare.com

Stephen Weaver, Finance Director

Tel: +1-412-826-5488 x151

sweaver@planthealthcare.com

Nomura Code Securities

Tel: +44 (0) 20 7776 1200

Claire Terlouw / Chris Golden

www.nomuracode.com

Powerscourt

Tel: +44 (0) 20 7250 1446

Paul Durman / Nick Dibden

paul.durman@powerscourt-group.com

nick.dibden@powerscourt-group.com

 

 

 

 

 

About Arysta LifeScience Corporation

Headquartered in Tokyo, Japan, Arysta LifeScience is the world's largest privately held crop protection and life science company with 2011 revenues of JPY125.8 billion (US$1.6 billion). An entrepreneurial provider of crop protection and life science products in more than 125 countries worldwide, Arysta LifeScience specialises in marketing and distribution of respected crop protection brands and life science products in harmony with the needs of global partners. More information on the company is available at: www.arystalifescience.com.

 

Contact:

Linda Frerichs Global Communications Manager

Arysta LifeScience Corporation

919-678-4948

linda.frerichs@arystalifescience.com

 

Tara Hart Public Relations Manager

Woodruff Sweitzer

816-255-1960

thart@woodruffsweitzer.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAELXAFPAEFF
Date   Source Headline
20th Apr 20227:00 amRNSHolding(s) in Company
19th Apr 20221:46 pmRNSNotice of results and investor presentation
11th Apr 202212:52 pmRNSHolding(s) in Company
1st Apr 20227:00 amRNSNew Distribution agreement with Ager Agro
14th Mar 202212:49 pmRNSHolding(s) in Company
11th Mar 202212:19 pmRNSHolding(s) in Company
3rd Feb 202212:56 pmRNSHolding(s) in Company
1st Feb 20221:16 pmEQSPlant Health Care, plc
1st Feb 20227:00 amRNS2021 Trading Statement
31st Jan 20227:00 amRNSPHC949 product registration submitted to the EPA
17th Jan 20227:00 amRNSInvestor Presentation
15th Dec 20217:00 amRNSWilbur Ellis and Plant Health Care discussion
13th Dec 20217:00 amRNSCommercial scale manufacturer for Saori
30th Nov 20214:36 pmRNSPrice Monitoring Extension
20th Oct 20216:03 pmRNSExercise of Options
22nd Sep 20217:00 amRNSNew agreement with Nutrien for Saori launch
22nd Sep 20217:00 amRNSInterim Report 30 June 2021
21st Sep 20214:41 pmRNSSecond Price Monitoring Extn
21st Sep 20214:35 pmRNSPrice Monitoring Extension
1st Sep 20217:00 amRNSArgentina approves Harpin as a seed treatment
24th Aug 20217:00 amRNSInvestor Presentation
18th Aug 20214:41 pmRNSSecond Price Monitoring Extn
18th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20211:27 pmRNSHolding(s) in Company
3rd Aug 20217:00 amRNSAdmission to the U.S. OTCQB Venture Market
27th Jul 20217:00 amRNSNew Distribution Agreement with Agrii UK
26th Jul 20217:00 amRNS2021 Half-Year Trading Statement
23rd Jul 20217:00 amRNSGrant of Options
22nd Jul 20217:00 amRNSInvestor Presentation
12th Jul 20214:40 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:35 pmRNSPrice Monitoring Extension
14th Jun 20212:33 pmRNSResult of AGM
14th Jun 20217:00 amRNSGreen Economy Mark awarded
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
20th May 20217:00 amRNSInvestor Presentation
7th May 20213:50 pmRNSAnnual Report & Accounts and AGM Notice Published
30th Apr 20215:40 pmRNSHolding(s) in Company
23rd Apr 20217:00 amRNSResults for the year ended 31 December 2020
21st Apr 202111:58 amRNSHolding(s) in Company
8th Apr 20213:30 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSTotal Voting Rights
22nd Mar 20217:00 amRNSInvestor Presentation
18th Mar 20211:57 pmRNSResults of Placing and Subscription
18th Mar 20217:00 amRNSProposed Placing and Subscription
1st Mar 20217:00 amRNSSaori Trial Update
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.